基于网络药理学–分子对接技术探讨银翘散对小儿急性上呼吸道感染及川崎病的异病同治作用机制
Exploring the Mechanism of Action of Yin Qiao San on Paediatric Acute Upper Respiratory Tract Infections and Kawasaki Disease Based on Network Pharmacology-Molecular Docking Technique for Heterogeneous Disease Treatment
摘要: 目的:基于网络药理学及分子对接技术探讨银翘散“异病同治”小儿急性上呼吸道感染(AURIC)与川崎病(KD)的共同潜在靶点及作用机制。方法:通过TCMSP数据库中查找银翘散中药物的潜在的活性化合物及靶点,通过Drug Bank,Gene Cards,TTD,OMIM和Pharm GKB数据库得到与AURIC、KD相关的靶基因。构建“药物–成分–靶点”网络,对交集靶蛋白进行GO和KEGG分析。最后对预测靶标和化合物进行分子对接验证。结果:获得108个活性成分,对应靶点257个,筛选疾病药物共同靶标142个,KEGG通路富集显示IL-17、PI3K/Akt、TNF是AURIC、KD相关的疾病通路。分子对接结果表明银翘散与BCL2、ESR1、TP53、MAPK1、AKT1均具有较强的结合活性。结论:银翘散对治疗AURIC、KD的异病同治作用具有多成分、靶点、多通路的特点。
Abstract: Objective: To investigate the common potential targets and mechanisms of action of Yin Qiao San in the treatment of paediatric acute upper respiratory tract infection (AURIC) and Kawasaki disease (KD) based on network pharmacology and molecular docking technology. Methods: The potential active compounds and targets of Yin Qiao San were identified in TCMSP database, and the target genes related to AURIC and KD were obtained from Drug Bank, Gene Cards, TTD, OMIM and Pharm GKB databases. A drug-component-target network was constructed, and GO and KEGG analyses were performed on the intersecting target proteins. Finally, the predicted targets and compounds were verified by molecular docking. Result: The results showed that 108 active ingredients were obtained, corresponding to 257 targets, and 142 common targets were screened. KEGG pathway enrichment showed that IL-17, PI3K/Akt, and TNF were the disease pathways related to AURIC and KD. The molecular docking results showed that Yin Qiao San had strong binding activity with BCL2, ESR1, TP53, MAPK1, AKT1. Conclusion: The heterogeneous and homoeopathic effects of Yin Qiao San on the treatment of AURIC and KD are characterised by multiple components, targets and pathways.
文章引用:郭方芳. 基于网络药理学–分子对接技术探讨银翘散对小儿急性上呼吸道感染及川崎病的异病同治作用机制[J]. 临床医学进展, 2024, 14(10): 664-673. https://doi.org/10.12677/acm.2024.14102711

参考文献

[1] 胡亚美, 江载芳, 申昆玲. 诸福棠实用儿科学[M]. 第8版. 北京: 人民卫生出版社, 2015: 1248-1249.
[2] 李立, 廖星, 赵静, 等. 中国小儿急性上呼吸道感染相关临床指南的解读[J]. 中国中药杂志, 2017, 42(8): 1510-1513.
[3] McCrindle, B.W., Rowley, A.H., Newburger, J.W., et al. (2017) Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals from the American Heart Association. Circulation, 135, e927-e999.
[4] 范雪, 徐明国. 川崎病发病机制及治疗研究进展[J]. 中国实用儿科杂志, 2021, 36(5): 340.
[5] 陈强, 訾慧芬, 侯毅, 等. 川崎病的诊治进展[J]. 中国中西医结合儿科学, 2020, 12(5): 387-388.
[6] Onouchi, Y. (2017) The Genetics of Kawasaki Disease. International Journal of Rheumatic Diseases, 21, 26-30. [Google Scholar] [CrossRef] [PubMed]
[7] Ding, Y., Li, G., Xiong, L., Yin, W., Liu, J., Liu, F., et al. (2015) Profiles of Responses of Immunological Factors to Different Subtypes of Kawasaki Disease. BMC Musculoskeletal Disorders, 16, Article No. 315. [Google Scholar] [CrossRef] [PubMed]
[8] 樊志丹, 俞海国, 胡坚, 等. 中国儿童血管炎诊断与治疗系列专家共识之四——川崎病[J]. 中国实用儿科杂志, 2023, 38(7): 485.
[9] 汪受传. 小儿急性上呼吸道病毒感染中医诊疗指南[J]. 南京中医药大学学报, 2011, 27(3): 204-208.
[10] 秦璨, 魏兵, 齐双辉. 川崎病血管损伤的中西医研究进展[J]. 实用中医内科杂志, 2020, 34(6): 44-45.
[11] 吴瑭. 温病条辨[M]. 北京: 人民卫生出版社, 2005: 16-19.
[12] 韩新民. 中医儿科学[M]. 第2版. 北京: 高等教育出版社, 2016.
[13] 马丽萍, 欧阳波, 谢方方, 等. 银翘散加减治疗急性上呼吸道感染疗效观察[J]. 中国医学文摘(耳鼻咽喉科学), 2022, 37(5): 104.
[14] 郭倩, 李金红, 李扬名. 银翘散联合丙种球蛋白和阿司匹林治疗川崎病的疗效及对患儿血清免疫功能和炎症因子的影响[J]. 河北中医, 2022, 44(4): 626.
[15] 牛明, 张斯琴, 张博, 等. 《网络药理学评价方法指南》解读[J]. 中草药, 2021, 52(14): 4119.
[16] Rigante, D. (2020) Kawasaki Disease as the Immune-Mediated Echo of a Viral Infection. Mediterranean Journal of Hematology and Infectious Diseases, 12, e2020039. [Google Scholar] [CrossRef] [PubMed]
[17] Domiciano, T.P., Wakita, D., Jones, H.D., Crother, T.R., Verri, W.A., Arditi, M., et al. (2017) Quercetin Inhibits Inflammasome Activation by Interfering with ASC Oligomerization and Prevents Interleukin-1 Mediated Mouse Vasculitis. Scientific Reports, 7, Article No. 41539. [Google Scholar] [CrossRef] [PubMed]
[18] 刘彩虹, 杨红辉, 卢俊娟. 山柰酚减轻慢性阻塞性肺疾病模型小鼠的炎症反应[J]. 中国病理生理杂志, 2021, 37(9): 1655.
[19] Li, S., Yang, T., Lai, C., Huang, S., Liao, J., Wan, L., et al. (2014) Antiviral Activity of Aloe-Emodin against Influenza a Virus via Galectin-3 Up-Regulation. European Journal of Pharmacology, 738, 125-132. [Google Scholar] [CrossRef] [PubMed]
[20] 张宜. 基于NLRP3通路探讨芦荟大黄素保护血管内皮的作用机制[D]: [硕士学位论文]. 广州: 广州中医药大学, 2022.
[21] Reece, M.D., Song, C., Hancock, S.C., Pereira Ribeiro, S., Kulpa, D.A. and Gavegnano, C. (2022) Repurposing BCL-2 and Jak 1/2 Inhibitors: Cure and Treatment of HIV-1 and Other Viral Infections. Frontiers in Immunology, 13, Article ID: 1033672. [Google Scholar] [CrossRef] [PubMed]
[22] Sabapathy, K. and Lane, D.P. (2019) Understanding P53 Functions through P53 Antibodies. Journal of Molecular Cell Biology, 11, 317-329. [Google Scholar] [CrossRef] [PubMed]
[23] Li, X., Bechara, R., Zhao, J., McGeachy, M.J. and Gaffen, S.L. (2019) IL-17 Receptor-Based Signaling and Implications for Disease. Nature Immunology, 20, 1594-1602. [Google Scholar] [CrossRef] [PubMed]
[24] 潘燕蝶, 潘小丹, 李洁, 等. 慢性阻塞性肺疾病继发肺部感染的炎性因子及TLR7/IL-23/IL-17信号通路作用[J]. 中华医院感染学杂志, 2020, 30(7): 997.
[25] Nandi, A., Pal, P. and Basu, S. (2019) A Comparison of Serum IL6 and CRP Levels with Respect to Coronary Changes and Treatment Response in Kawasaki Disease Patients: A Prospective Study. Rheumatology International, 39, 1797-1801. [Google Scholar] [CrossRef] [PubMed]
[26] Xie, X., Shi, X. and Liu, M. (2017) The Roles of Genetic Factors in Kawasaki Disease: A Systematic Review and Meta-Analysis of Genetic Association Studies. Pediatric Cardiology, 39, 207-225. [Google Scholar] [CrossRef] [PubMed]
[27] 郭鑫, 刘琮, 王国兵, 等. 川崎病冠状动脉内皮细胞损伤的定量蛋白组学研究与生物信息学分析[J]. 中国当代儿科杂志, 2020, 22(7): 802.